Which Stocks Lose From Trade War?
After stock sentiment worsened to start Monday morning’s trading, it reversed quickly when the U.S. delayed its tariff on Mexico by one month. Mexico agreed to protect the borders, with 10,000 troops.In Canada, calls to slap Tesla (TSLA) with 100% tariffs put the stock in a losing position. Although the sales loss does not hurt Tesla much, the symbolic gesture does not help the electric vehicle leader. With U.S. tariffs on China at 10%, investors should also avoid EV firms in that country. That includes Li Auto (LI), Nio (NIO), XPeng (XPEV), and BYD (BYDDF).Ontario planned to stop selling U.S. alcohol. A prolonged trade war would hurt beer firms like Ambev (ABEV), Anheuser-Busch InBev (BUD), and Constellation Brands (STZ). Consumers would likely decrease the purchase of alcohol producers, regardless of their country of origin.The automotive sector will lose out from the trade war. Auto manufacturers have a deeply intertwined supply chain between the U.S., Canada, and Mexico. The indiscriminate tariff adds costs for Ford Motor (F) and General Motors (GM). Car supply firms like Aptiv (APTV) and Magna (MGA) will face lower margins as costs rise and demand falls. Mid-sized companies in the food sector will face higher costs. Instead, investors should stick with big restaurant and food supplier names. In the former, consider Domino’s (DPZ) and Starbucks (SBUX). In the latter case, Mondelez (MDLZ) and Danone (DANOY) will face minimal disruptions from tariffs.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


